Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Checkpoint Therapeutics Inc CKPT

Healthcare Biotechnology
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber... see more

Recent & Breaking News (NDAQ:CKPT)

Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire November 8, 2022

Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire September 22, 2022

Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire September 8, 2022

Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire August 12, 2022

Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma

GlobeNewswire June 16, 2022

Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire June 6, 2022

Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

GlobeNewswire May 19, 2022

Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency

GlobeNewswire May 13, 2022

Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire May 12, 2022

Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 28, 2022

Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

GlobeNewswire April 4, 2022

Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022

GlobeNewswire April 1, 2022

Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

GlobeNewswire March 28, 2022

Checkpoint Therapeutics to Participate in the B. Riley Securities' Virtual Oncology Conference

GlobeNewswire January 25, 2022

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

GlobeNewswire January 25, 2022

Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer

GlobeNewswire December 8, 2021

Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results

GlobeNewswire November 4, 2021

Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

GlobeNewswire September 22, 2021

Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire September 9, 2021

Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results

GlobeNewswire August 5, 2021